Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proof-of-Concept Case-Control Study for Hepatocellular Carcinoma Identification Using Delta-HLD Technology (HIDE)

NCT07148310 is registered in ClinicalTrials.gov with Epiliquid Holding, Inc as lead sponsor.

NCT NCT07148310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07148310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proof-of-Concept Case-Control Study for Hepatocellular Carcinoma Identification Using Delta-HLD Technology (HIDE)
Lead sponsor
Epiliquid Holding, Inc
Phase
Observational
Overall status
Recruiting
Start date
May 18, 2023
Completion date
December 31, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepato cellular carcinoma (hcc)